ProteoNic licenses protein production tech to GenScript ProBio

By The Science Advisory Board staff writers

June 17, 2022 -- ProteoNic is licensing its 2G UNic technology for boosting therapeutic protein production to GenScript ProBio, a global contract development and manufacturing organization. The protein expression technology improves production levels across a range of mammalian host cells, selection systems, and protein targets.

Under the agreement, for which financial terms were not disclosed, GenScript ProBio will gain access to ProteoNic technology for the development of high yielding cell lines for its clients. Also, GenScript ProBio clients will profit from reduced cost of goods for their products as well as increased product development efficiency and capacity, the firms said.

ProteoNic, NecstGen partner on viral vector manufacturing
ProteoNic and NecstGen are partnering to develop improved viral vector manufacturing for gene therapy applications, specifically using adeno-associated...
GenScript ProBio, AskGene ink licensing deal
GenScript ProBio and AskGene have signed a nonexclusive licensing agreement covering the use of GenScript ProBio's single-domain antibody to target an...
ProteoNic licenses tech to Gilead for biologics production
ProteoNic has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences.

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter